Argus Research Maintains Buy on Medtronic, Lowers Price Target to $115

Benzinga Newsdesk www.benzinga.com Negative 48.3%

Neg 48.3% Neu 0% Pos 0%

Argus Research analyst David Toung maintains Medtronic (NYSE:MDT) with a Buy and lowers the price target from $125 to $115.